FDA Determines Regulatory Review Period for AVEIR VR Leadless System

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for the AVEIR VR Leadless System, a medical device, following patent extension applications submitted to the US Patent and Trademark Office (USPTO).